Creating new drugs to help treat resistant breast and lung cancers
Official title: Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-10900479 · Data updated 2026-11-12
This study is looking at new ways to stop certain proteins that help cancer cells resist treatment, especially in HER2-positive breast cancer and KRAS-driven lung cancer, with the hope of creating better therapies that work more effectively for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | July 12, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $649,046 |
| NIH project number | 5R01CA262530-04 |
| Project ID | NIH-10900479 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with HER2-positive breast cancer or KRAS-driven lung cancer who have experienced treatment resistance.
✕Less likely to help
Patients with cancers that do not involve HER2 or KRAS mutations may not benefit from this research.
What this research studies
This research focuses on developing new inhibitors that target CDK12 and CDK13, which are proteins involved in cancer cell adaptation to treatments. By blocking these proteins, the goal is to prevent cancer cells from becoming resistant to therapies, particularly in HER2-positive breast cancers and KRAS-driven lung cancers. The research involves identifying how these proteins change cancer cell behavior and finding ways to exploit these changes to improve treatment outcomes. Patients may benefit from new therapies that are more effective against their cancers.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with resistant breast and lung cancers.
How similar studies have gone: Previous research has shown promise in targeting CDK12 and CDK13 to combat drug resistance in cancer, indicating a potential for success in this approach.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Duckett, Derek Ronald — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Duckett, Derek Ronald
Related research
Other NIH-funded projects on the same topics.
-
TRIM28 Inhibition for NOTCH2-Mutant Small Cell Lung Cancer
A new approach aims to exploit a weakness in a subset of small cell lung cancer by turning on immune-related signals when NOTCH2 is lost, potentially making tumors more visible to the immune system.
-
Genomic factors shaping lung cancer risk in Native Hawaiians and Pacific Islanders
This NIH grant focuses on understanding why Native Hawaiians, Pacific Islanders, and African Americans have higher lung cancer risk and poorer outcomes by studying tumor DNA and related molecular patterns.
-
PD-L1 PET tracer to guide immune therapy in non-small cell lung cancer
A Johns Hopkins team is testing a Gallium-68 PET tracer to better guide immune checkpoint therapy for people with non-small cell lung cancer.
-
Targeting SMARCA2 to treat lung cancers that lack SMARCA4
This work looks at whether blocking a protein called SMARCA2 can slow or stop lung cancers that have lost the related gene SMARCA4.
-
New medicines for lung cancers caused by KRAS or BRAF changes
Testing new medicines that block ERK/RAF signaling in people with lung cancer driven by KRAS or BRAF mutations.
-
Understanding lung cancer risks in Native Hawaiians
This research looks at the genetic differences in lung cancer among Native Hawaiians to better understand why they face higher risks and poorer outcomes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.